Patents by Inventor Ahmed M. Al-Hejin

Ahmed M. Al-Hejin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NK-LYSIN PEPTIDE COMPOSITIONS AND METHODS FOR THEIR USE AS ANTIMICROBIAL/ANTIVIRAL AGENTS
    Publication number: 20220305093
    Abstract: Natural killer (NK)-lysin peptides from chicken, bovine and human species are used as an antimicrobial or antiviral agent alone or in combination with other agents. A pharmaceutical composition comprising NK-lysin peptides was effective against Rotavirus and various gram-negative and gram-positive bacteria that were tested. Combinations of NK-lysin peptides plus silver nanoparticles or IL-2 were also effective against Salmonella typhimurium. Treatment with the NK-lysin peptides repressed ?-lactam-resistance genes (CTX-M-1, CTX-M-8 and CTX-M-9) in bacterial species tested and thus can be used to augment treatment with ?-lactams and increase bacterial sensitivity to this important class of antibiotics.
    Type: Application
    Filed: January 12, 2022
    Publication date: September 29, 2022
    Inventors: Maged Mostafa MAHMOUD, Haitham A. YACOUB, Ahmed M. AL-HEJIN, Turki ABUJAML, Sherif ABD-ELMAKSOUD
  • NK-lysin peptide compositions and methods for their use as antimicrobial/antiviral agents
    Patent number: 11433122
    Abstract: Natural killer (NK)-lysin peptides from chicken, bovine and human species are used as an antimicrobial or antiviral agent alone or in combination with other agents. A pharmaceutical composition comprising NK-lysin peptides was effective against Rotavirus and various gram-negative and gram-positive bacteria that were tested. Combinations of NK-lysin peptides plus silver nanoparticles or IL-2 were also effective against Salmonella typhimurium. Treatment with the NK-lysin peptides repressed ?-lactam-resistance genes (CTX-M-1, CTX-M-8 and CTX-M-9) in bacterial species tested and thus can be used to augment treatment with ?-lactams and increase bacterial sensitivity to this important class of antibiotics.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: September 6, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Maged Mostafa Mahmoud, Haitham A. Yacoub, Ahmed M. Al-Hejin, Turki Abujaml, Sherif Abd-Elmaksoud
  • NK-lysin peptide compositions and methods for their use as antimicrobial/antiviral agents
    Patent number: 11260113
    Abstract: Natural killer (NK)-lysin peptides from chicken, bovine and human species are used as an antimicrobial or antiviral agent alone or in combination with other agents. A pharmaceutical composition comprising NK-lysin peptides was effective against Rotavirus and various gram-negative and gram-positive bacteria that were tested. Combinations of NK-lysin peptides plus silver nanoparticles or IL-2 were also effective against Salmonella typhimurium. Treatment with the NK-lysin peptides repressed ?-lactam-resistance genes (CTX-M-1, CTX-M-8 and CTX-M-9) in bacterial species tested and thus can be used to augment treatment with ?-lactams and increase bacterial sensitivity to this important class of antibiotics.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: March 1, 2022
    Assignee: King Abdulaziz University
    Inventors: Maged Mostafa Mahmoud, Haitham A. Yacoub, Ahmed M. Al-Hejin, Turki Abujaml, Sherif Abd-Elmaksoud
  • Chicken cathelicidins as a cancer therapy
    Patent number: 11179438
    Abstract: Methods of treating cancer, such as breast cancer or colorectal cancer, in a subject are provided. The methods include administering to the subject a therapeutically effective amount of a chicken cathelicidin, such as cathelicidin-1, cathelicidin-2, or cathelicidin-3. Methods of inhibiting the growth of cancer cells are also provided.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: November 23, 2021
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Maged M. Mahmoud, Haitham A. Yacoub, Ahmed M. Al-Hejin, Turki Abujaml, Fadwa Aljoud, Modhi Alenezi, Abdulwahab Noorwali